研究单位：[1]Shanghai Junshi Bioscience Co.,Ltd.[2]Beijing Cancer Hospital Beijing,China[3]Peking University Third Hospital Beijing,China[4]The General Hospital of People's Liberation Army Beijing,China[5]Heping Hospital Affiliated to changzhi Medical College Changzhi,China[6]Sichuan Cancer Hospital & Institute Chengdu,China[7]Fujian Cancer Hospital Fuzhou,China[8]3201 Hospital Hangzhou,China[9]Zhejiang Cancer Hospital Hangzhou,China[10]The First Affiliated Hospital,Zhejiang University School of Medicine Hanzhou,China[11]harbin medical university Cancer Hospital Harbin,China
研究目的：
This is a randomized,placebo-controlled,multi-center,double-blinded,Phase III study to determine the efficacy and safety of patients with locally advanced squamous cell carcinoma of the thoracic esophagus treated with perioperative immunotherapy combined with neoadjuvant chemotherapy versus placebo combined with neoadjuvant chemotherapy.
